PMID- 16038481
OWN - NLM
STAT- MEDLINE
DCOM- 20050916
LR  - 20091119
IS  - 1359-6535 (Print)
IS  - 1359-6535 (Linking)
VI  - 10
IP  - 4
DP  - 2005
TI  - Interactive selective pressures of HLA-restricted immune responses and 
      antiretroviral drugs on HIV-1.
PG  - 551-5
AB  - HIV-specific cytotoxic T lymphocyte (CTL) responses mediated by human leukocyte 
      antigen (HLA) recognition and antiretroviral drugs exert selection pressure on 
      HIV-1 in vivo. The selection of CTL escape mutations strongly underpins the 
      failure of CTL control in most untreated infections whilst drug-resistance 
      mutations predict failure of drug control. These two evolutionary forces share 
      common target residues in HIV-1 at which their selection effects could be 
      synergistic or antagonistic, such that the propensity to develop drug resistance 
      and virological treatment failure may be influenced by HLA type. We examined 
      HIV-1 reverse transcriptase (RT) and protease sequences in a large clinical 
      observational cohort of 487 HIV-infected individuals and found evidence of 
      site-specific interactions between specific antiretroviral drug exposures, HLA 
      alleles and HIV sequence diversity at population level. Such interactions may 
      have general and specific implications for explaining in vivo/in vitro 
      discordance of drug resistance, host-specific susceptibility to drug resistance, 
      individualization of therapy and therapeutic vaccine design.
FAU - John, Mina
AU  - John M
AD  - Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital 
      and Murdoch University, Perth, WA, Australia.
FAU - Moore, Corey B
AU  - Moore CB
FAU - James, Ian R
AU  - James IR
FAU - Mallal, Simon A
AU  - Mallal SA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Antivir Ther
JT  - Antiviral therapy
JID - 9815705
RN  - 0 (Anti-HIV Agents)
RN  - 0 (HLA Antigens)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - EC 3.4.23.- (HIV Protease)
SB  - IM
MH  - Anti-HIV Agents/*pharmacology
MH  - Drug Resistance, Viral/*genetics
MH  - Genetic Variation
MH  - HIV Infections/drug therapy/immunology/virology
MH  - HIV Protease/genetics
MH  - HIV Reverse Transcriptase/genetics
MH  - HIV-1/drug effects/*genetics/immunology
MH  - *HLA Antigens
MH  - Humans
MH  - Mutation
MH  - *Selection, Genetic
MH  - T-Lymphocytes, Cytotoxic
EDAT- 2005/07/26 09:00
MHDA- 2005/09/17 09:00
CRDT- 2005/07/26 09:00
PHST- 2005/07/26 09:00 [pubmed]
PHST- 2005/09/17 09:00 [medline]
PHST- 2005/07/26 09:00 [entrez]
PST - ppublish
SO  - Antivir Ther. 2005;10(4):551-5.